----

|                         |
|------------------------------|
| FORM 20-F/A(Amendment No. 1) |
|                         |
| Israel                                          |   | 2 HaMa’ayan Street                Modi’in 7177871, Israel |
|-------------------------------------------------|--------|-----------------------------------------------------------------------|
| (Jurisdiction of incorporation or organization) |   | (Address of principal executive offices)                              |
| Title of each class                                                                            |   | Name of each exchange on which registered |
|------------------------------------------------------------------------------------------------|--------|-------------------------------------------|
| American Depositary Shares, each representing 15 ordinary shares, par value NIS 0.10 per share |   | Nasdaq Capital Market                     |
|                                                                                           |   |                                      |
| Ordinary shares, par value NIS 0.10 per share                                                  |   | Nasdaq Capital Market*                    |
|                                                                                           |   |                                      |

----

| Large accelerated filer ☐ | Accelerated filer ☒ | Non-accelerated filer ☐ | Emerging growth company ☐ |
|---------------------------------|---------------------------|-------------------------------|---------------------------------|
| U.S. GAAP ☐ | International Financial Reporting Standards as issued by theInternational Accounting Standards Board ☒ | Other ☐ |
|-------------------|--------------------------------------------------------------------------------------------------------------|---------------|

----

| ExhibitNumber |   | Exhibit Description                                                                                                                                                                                                               |
|---------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12.1          |        | Certification by Chief Executive Officer pursuant to                  Section 302 of the Sarbanes-Oxley Act of 2002                                                                                                               |
| 12.2          |        | Certification by Chief Financial Officer pursuant to                  Section 302 of the Sarbanes-Oxley Act of 2002                                                                                                               |
| 13.1          |        | Certification by Chief Executive Officer pursuant to 18                  U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                |
| 13.2          |        | Certification by Chief Financial Officer pursuant to 18                  U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                                |
| 15.1          |        | Consent of Kesselman & Kesselman, Certified Public                  Accountants (Isr.), a Member  firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant |

----

|   | BIOLINERX LTD. |                    |
|--------|----------------|-------------------------|
|   |           |                    |   |
|   | By:            | /s/ Philip A. Serlin    |   |
|   |           | Philip A. Serlin        |   |
|   |           | Chief Executive Officer |   |

----